首页> 外国专利> Oligonucleotu00ecdeos, use and method for typing, the determination of viral dominance and quantification on the human papilomavu00ecrus using a combination of molecular techniques.Oligonucleotu00ecdeos and compounds.

Oligonucleotu00ecdeos, use and method for typing, the determination of viral dominance and quantification on the human papilomavu00ecrus using a combination of molecular techniques.Oligonucleotu00ecdeos and compounds.

机译:寡核苷酸,分型的用途和方法,结合分子技术对人乳头瘤病毒的病毒优势度的确定和定量。寡核苷酸和化合物。

摘要

"Oligonucleotu00ecdeos, use and method for typing, the determination of viral dominance and quantification on the human papilomavu00ecrus using a combination of molecular techniques.Oligonucleotu00ecdeos and compounds ".The present invention relates to the combined use of molecular biology techniques.Specifically, the nested multiplex PCR technology (polymerase chain reaction doubled) with general consensus oligonucleotides followed by multiple pairs of oligonucleotides specific and COmponentes (reagents and reaction conditions) for tipar the human papillomavirus in biological samples from human tissues, such as cervical swab, scraped the penis, mouth swab,Among others. Originally this invention amplifies at least 40 HPV types in general, then specific 32 types (SEQ.ID numbers 1 to 70) that may potentially be infected samples of human tissue.The procedures include the determination of multiple infections combined with the acquisition of the relationship of the viral load between the HPV types.Also called viral dominance in a particular stage of infection.32 viral types are described as part of a kit of multiplex PCR for simultaneous detection and typing of the virus.The sequ00b3u00eancias primers (specific primers or oligonucleotides) general consensus degenerate (1 a PCR reaction) and combined.As well as the specific primers combined (2 a PCR reaction (nested) for viral types, which include non oncogu00eanicos, oncogu00eanicos and indeterminate; 6, 11, 16, 18, 26, 30, 31, 33, 34, 35.39, 40, 42, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 70, mm7, mm8 and mm9.The quantification of viral infections among the types in multiple series of dilutions of DNA template amplification, after the initial general (1 a PCR) is determined.Both the viral dominance during clinical follow-up of the patients.The purpose of the dilution prior to amplification is to obtain a profile of bands of infective viral types.Allowing the determination of the relative proportion between specimens of HPV present in the sample tested, as well as their variations during the progress of infection.
机译:寡核苷酸,分型的用途和方法,使用分子技术的组合在人乳头瘤病毒上确定病毒优势度和定量。寡核苷酸和化合物。本发明涉及分子的组合用途具体来说,巢式多重PCR技术(聚合酶链式反应加倍)与一般的共有寡核苷酸,然后是多对特异的寡核苷酸和COmponentes(试剂和反应条件)对,用于人类组织(例如宫颈)的生物样品中的人乳头瘤病毒拭子,刮阴茎,口腔拭子,等等。最初,本发明通常扩增至少40种HPV类型,然后扩增可能被感染的人体组织样本中的特定32种类型(SEQ.ID 1至70)。该程序包括确定多种感染以及结合该关系HPV类型之间的病毒载量。在特定感染阶段也称为病毒优势.32种病毒类型被描述为同时检测和分型病毒的多重PCR试剂盒的一部分.seq u00b3 u00eancias引物(通用引物(1 PCR反应)并结合在一起。以及针对病毒类型的特异性引物(2 PCR反应(嵌套))结合在一起,包括非oncog u00eanicos,oncog u00eanicos和不确定; 6,11,16,16,18,26,30,31,33,34,35.39,40,42,44,45,51,52,53,54,55,56,57,58,59,61 ,62,64,66,67,68,70,mm7,mm8和mm9。确定最初的常规(1 PCR)后,DNA模板扩增的多个系列稀释液。在患者临床随访期间,病毒均处于优势地位。扩增之前稀释液的目的是获得可以确定测试样品中存在的HPV标本之间的相对比例以及它们在感染过程中的变化。

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号